Bain Capital Life Sciences Investors, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001703031

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 21 positions · Total reported value $1.68B · Top-10 concentration 87.9% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 33.3% · 3 new · 3 cut · 2 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q2 2026 13F filing, Bain Capital Life Sciences Investors, LLC disclosed 21 equity positions with a combined reported value of $1.68B. The filing implies a focused portfolio: its ten largest positions account for 87.9% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were KLRA ($497.51M), HTFL ($247.87M), NAMS ($129.00M). By sector, the heaviest allocations are Health Care 99.0%, Industrials 0.9%. Versus the prior quarter, allocation shifted toward Health Care (+3.2pp) and away from Industrials (-0.9pp), Other (-2.3pp).

Versus the prior quarter, Bain Capital Life Sciences Investors, LLC opened 3 new positions, trimmed 3 and fully exited 2, a turnover rate of 33.3% of positions. The portfolio's overlap with the prior quarter was 86% of names.

The largest new positions opened in Q2 2026 were KLRA ($497.51M), COAG ($60.60M).

Of the 2 positions fully exited versus the prior quarter, the largest were CNTA ($25.22M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • KLRA KAILERA THERAPEUTICS INC · $497.51M
  • COAG HEMAB THERAPEUTICS HLDGS INC · $60.60M

Fully Exited (vs previous quarter)

  • CNTA CENTESSA PHARMACEUTICALS PLC · prev qtr: $25.22M

Insider Transactions (Form 4)

Latest Bain Capital Life Sciences Investors, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-04-30 Sell Heartflow, Inc. 56,224 $30.05 SEC filing
2026-04-30 Sell Heartflow, Inc. 892,533 $29.18 SEC filing
2026-04-29 Sell Heartflow, Inc. 797,133 $29.37 SEC filing
2026-04-28 Sell Heartflow, Inc. 254,110 $30.51 SEC filing
2026-04-20 Buy Kailera Therapeutics, Inc. 1,562,500 $16.00 SEC filing
2026-04-20 Conversion Kailera Therapeutics, Inc. 4,145,768 — SEC filing
2026-04-20 Conversion Kailera Therapeutics, Inc. 16,875,000 — SEC filing

All insider transactions →

Fund Profile

Bain Capital Life Sciences Investors, LLC files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 21 positions worth $1.68B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 21 positions · $1.68B reported value (Q2 2026)
  • Top 10 holdings = 87.9% of reported value
  • Largest position: KLRA (KAILERA THERAPEUTICS INC) at 29.6%
  • Average position size: $80.10M

Sector Tilt

  • Health Care 99.0%
  • Industrials 0.9%
  • Materials 0.1%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 2 new, 2 added, 7 reduced, 1 exited
  • 10 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund appears to maintain a positive outlook on the healthcare sector, particularly within life sciences, with a focus on new investments in potentially high-growth companies. Despite reducing positions in some holdings, the overall increase in total value suggests a continued interest in the industry. 2. Key Moves: - New Holdings: The fund added new positions in Kailera Therapeutics (KLRA) and Hemab Therapeutics Holdings (COAG). It also initiated exposure to Caballetta Bio Inc (CABA) with a significant increase in shares. - Reductions: Heartflow Inc (HTFL) and NewAmsterdam Pharma Company (NAMS) saw their shares reduced significantly, with NAMS witnessing a particularly substantial decrease of nearly 48%. - Increases: The fund added shares in Alkermes PLC (ALKS) and slightly increased its holding in Solid Biosciences Inc (SLDB). 3. Portfolio Structure: The portfolio exhibits an active management style, with a clear sector bias towards healthcare, particularly in life sciences. The risk appetite seems to be moderate, with a preference for growth companies. The addition of new holdings and the reduction of some positions suggest a strategy of actively managing exposure to specific companies and sectors. 4. Per-Holding One-Liner: - KLRA: Kailera Therapeutics Inc (Health Care) - Developing therapies for rare and genetic diseases. - HTFL: Heartflow Inc (Health Care) - Provides advanced 3D modeling and analysis software for cardiovascular patients. - NAMS: NewAmsterdam Pharma Company (Health Care) - Specializes in the development of novel therapies for neurodegenerative diseases. - SVRA: Sarava Inc (Health Care) - Focuses on the development of next-generation cell therapies for cancer. - ALKS: Alkermes PLC (Health Care) - Develops novel therapies for chronic diseases, including addiction and central nervous system disorders. - SLDB: Solid Biosciences Inc (Health Care) - Engaged in the development of cures for rare genetic diseases. - PHVS: Pharvaris NV (Health Care) - Develops innovative treatments for liver disease. - OLMA: Olema Pharmaceuticals Inc (Health Care) - Focuses on the development of cancer therapies. - COAG: Hemab Therapeutics Holdings (Health Care) - Developing therapies for hemophilia and other bleeding disorders. - CABA: Caballetta Bio Inc (Health Care) - Specializes in the development of novel gene therapies for genetic diseases. 5. One-Sentence Style Summary: Bain Capital Life Sciences Investors LLC's Q2 2026 rebalancing reflects a strategic focus on diversifying within the life sciences sector, targeting growth opportunities while maintaining a balanced exposure to various healthcare sub-sectors.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 99.0%
Materials 0.1%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 22.58M $497.51M 29.58%
29.58%
New
2 8.45M $247.87M 14.74%
14.74%
Reduce
3 3.81M $129.00M 7.67%
7.67%
Reduce
4 17.60M $108.42M 6.45%
6.45%
Hold
5 1.94M $101.54M 6.04%
6.04%
Add
6 9.81M $97.99M 5.83%
5.83%
Hold
7 2.68M $92.52M 5.50%
5.50%
Hold
8 7.09M $88.64M 5.27%
5.27%
Reduce
9 1.65M $60.60M 3.60%
3.60%
New
10 17.24M $53.62M 3.19%
3.19%
Add
11 7.97M $37.21M 2.21%
2.21%
Hold
12 362.47K $35.33M 2.10%
2.10%
Hold
13 7.17M $33.49M 1.99%
1.99%
Hold
14 2.88M $25.71M 1.53%
1.53%
Reduce
15 4.44M $25.34M 1.51%
1.51%
Reduce
16 8.43M $14.59M 0.87%
0.87%
Hold
17 141.23K $10.33M 0.61%
0.61%
Hold
18 2.08M $9.65M 0.57%
0.57%
Reduce
19 664.02K $6.36M 0.38%
0.38%
Hold
20 600.95K $4.16M 0.25%
0.25%
Reduce
21 100.00K $2.14M 0.13%
0.13%
Hold

FAQ

What did Bain Capital Life Sciences Investors, LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, Bain Capital Life Sciences Investors, LLC reported 21 equity positions worth $1.68B in aggregate; its largest disclosed positions were KLRA ($497.51M), HTFL ($247.87M), NAMS ($129.00M).

How large is Bain Capital Life Sciences Investors, LLC's portfolio?

Bain Capital Life Sciences Investors, LLC reported $1.68B of long equity holdings across 21 positions as of 2026-Q2. Top-10 holdings account for 87.9% of reported value.

What is Bain Capital Life Sciences Investors, LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/bain-capital-life-sciences-investors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →